Literature DB >> 16095934

Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.

Harald Breivik1, Beverly Collett, Vittorio Ventafridda, Rob Cohen, Derek Gallacher.   

Abstract

UNLABELLED: This large scale computer-assisted telephone survey was undertaken to explore the prevalence, severity, treatment and impact of chronic pain in 15 European countries and Israel. Screening interviews identified respondents aged 18 years with chronic pain for in-depth interviews. 19% of 46,394 respondents willing to participate (refusal rate 46%) had suffered pain for 6 months, had experienced pain in the last month and several times during the last week. Their pain intensity was 5 on a 10-point Numeric Rating Scale (NRS) (1 = no pain, 10 = worst pain imaginable) during last episode of pain. In-depth interviews with 4839 respondents with chronic pain (about 300 per country) showed: 66% had moderate pain (NRS = 5-7), 34% had severe pain (NRS = 8-10), 46% had constant pain, 54% had intermittent pain. 59% had suffered with pain for two to 15 years, 21% had been diagnosed with depression because of their pain, 61% were less able or unable to work outside the home, 19% had lost their job and 13% had changed jobs because of their pain. 60% visited their doctor about their pain 2-9 times in the last six months. Only 2% were currently treated by a pain management specialist. One-third of the chronic pain sufferers were currently not being treated. Two-thirds used non-medication treatments, e.g,. massage (30%), physical therapy (21%), acupuncture (13%). Almost half were taking non-prescription analgesics; 'over the counter' (OTC) NSAIDs (55%), paracetamol (43%), weak opioids (13%). Two-thirds were taking prescription medicines: NSAIDs (44%), weak opioids (23%), paracetamol (18%), COX-2 inhibitors (1-36%), and strong opioids (5%). Forty percent had inadequate management of their pain. Interesting differences between countries were observed, possibly reflecting differences in cultural background and local traditions in managing chronic pain.
CONCLUSIONS: Chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Very few were managed by pain specialists and nearly half received inadequate pain management. Although differences were observed between the 16 countries, we have documented that chronic pain is a major health care problem in Europe that needs to be taken more seriously.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16095934     DOI: 10.1016/j.ejpain.2005.06.009

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  1223 in total

1.  Functional inhibition of erectile process in rats by indomethacin.

Authors:  Amira M Senbel
Journal:  World J Urol       Date:  2010-10-07       Impact factor: 4.226

Review 2.  Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

3.  Prayer and pain: the mediating role of positive re-appraisal.

Authors:  Jessie Dezutter; Amy Wachholtz; Jozef Corveleyn
Journal:  J Behav Med       Date:  2011-04-23

Review 4.  Health economics of interdisciplinary rehabilitation for chronic pain: does it support or invalidate the outcomes research of these programs?

Authors:  Annette Becker
Journal:  Curr Pain Headache Rep       Date:  2012-04

Review 5.  [Efficacy, utility and cost-effectiveness of multidisciplinary treatment for chronic low back pain].

Authors:  C Rolli Salathé; A Elfering; M Melloh
Journal:  Schmerz       Date:  2012-04       Impact factor: 1.107

Review 6.  Dysregulated Src upregulation of NMDA receptor activity: a common link in chronic pain and schizophrenia.

Authors:  Michael W Salter; Graham M Pitcher
Journal:  FEBS J       Date:  2011-12-05       Impact factor: 5.542

Review 7.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

8.  [The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].

Authors:  H-G Schaible
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

9.  What comprises a good outcome in spinal surgery? A preliminary survey among spine surgeons of the SSE and European spine patients.

Authors:  M Haefeli; A Elfering; M Aebi; B J C Freeman; P Fritzell; J Guimaraes Consciencia; C Lamartina; M Mayer; T Lund; N Boos
Journal:  Eur Spine J       Date:  2007-11-08       Impact factor: 3.134

10.  [Prevalence of chronic pain in Germany. A representative survey of the general population].

Authors:  W Häuser; G Schmutzer; A Hinz; A Hilbert; E Brähler
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.